Exhibit 10.14.1



 


CONSULTING AND INTELLECTUAL PROPERTY (“IP”)
AGREEMENT


 


This Consulting and
IP Agreement (this “Agreement”) is effective as of August 1, 2011, (the “Effective Date”)
and is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware,
with registered office at 18 Desbrosses Street, New-York 10013 NY, USA (“INTERCEPT”)
on the one hand and ROBERTO PELLICCIARI (“Consultant”), residing at Via U. Rocchi, 60, Perugia, Italy
06123, on the other hand.


 


RECITALS


 


WHEREAS, INTERCEPT desires to utilize
Consultant to provide scientific guidance, supervision and coordination (the “Services”) of a research program (the
“Research Program”) that will be undertaken by TES, to discover Compounds (“Compounds” as defined below)
and to act as INTERCEPT’s designated representative to a joint steering committee formed pursuant to a research collaboration
agreement between INTERCEPT and LES LABORATOIRES SERVIER (the “Research Collaboration”);


 


WHEREAS, TES is a corporation engaged
in the business of drug discovery;


 


WHEREAS, Roberto
Pellicciari is (i) a part-time Professor at the Dipartimento di Chimica e Tecnologia del Farmaco of the Università di Perugia
(the “University”) and (ii) an owner of TES;


 


WHEREAS, INTERCEPT desires to obtain
certain rights to Inventions, Know How, Improvements and Patent Rights (defined below) arising out of or in connection with such
Research Program and consulting agreement with Consultant; and


 


WHEREAS, Consultant is willing to
provide the Services and grant to INTERCEPT such rights under terms and conditions set forth herein.


 


NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, Consultant and INTERCEPT hereby agree as follows:


 


Article
1: DEFINITIONS


 


Unless specifically set forth to the contrary herein, the following
terms, whether used in the singular or plural, shall have the respective meanings set forth below.


 


		1.1	“Affiliate” means (1)
any corporation or business entity of which fifty percent (50%) or more of the securities or other ownership interests representing
the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by Consultant,
or INTERCEPT; or (2) any corporation or business entity which, directly or indirectly, owns, controls or holds fifty percent (50%)
(or the maximum ownership interest permitted by law) or more of the securities or other ownership interests representing the equity,
the voting stock or, if applicable, the general partnership interest, of Consultant or INTERCEPT; or (3) any corporation or business
entity of which fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting
stock or general partnership interest are owned, controlled or held, directly or indirectly, by a corporation or business entity
described in (1) or (2). 






 


Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.


 








    	page 1 of 13



    	 



    

  


		1.2	“Agreement” means this
agreement, including all exhibits attached hereto.



 


		1.3	“Calendar Quarter”
means each period of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.



 


		1.4	“Compound(s)” means
any chemical entity and/or active ingredient which is a selective or non-selective TGR5 receptor agonist or [***], including any
Derivative thereof, discovered and synthesized by Consultant, TES  or its Affiliates
pursuant to work conducted under the Research Program. 



 


		1.5	“Control,” “Controls,”
or “Controlled by” means, with respect to any item of or right under Patent Rights, Know-How, the possession
of (whether by ownership or license, other than pursuant to this Agreement) or the ability of a Party to grant access to, or a
license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement
with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license
or sublicense.



 


		1.6	“Data” means all non-clinical
data, research data and manufacturing data (including stability data, chemical data and quality control data) pertaining to any
Compound, which are Controlled by either Party at any time during the Term of this Agreement.



 


		1.7	“Derivative” shall
mean any chemical entity, the chemical structure of which was derived on the basis of structure-activity relationship data obtained
with a Compound or series of Compounds.



 


		1.8	“Effective Date”
means the date on which this Agreement is entered into by and between INTERCEPT and Consultant. 



 


		1.9	“Euros” means the official
currency of the European Union.



 


		1.10	“GLP” or “Good
Laboratory Practice” means the framework within which: (i) laboratory studies are planned, performed, monitored, recorded,
reported and archived as defined under 21 CFR 58, OECD Principles on Good Laboratory Practice (ENV/MC/Chem (98)17), Directive 2004/10/EC
and equivalent regulations as amended from time to time.



 


		1.11	“Improvements” shall
mean and include [***].



 


		1.12	“Information” means
any and all information and data, including without limitation all Consultant Know-How, TES Know-How, all INTERCEPT Know-How, and
all other scientific, non clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data,
whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection
with this Agreement.



 


		1.13	“Invention(s)” means
any process, method, composition of matter, article of manufacture, discovery or finding, patentable or not patentable, that is
conceived and reduced to practice by a Party solely or jointly by the Parties or their Affiliates or consultants, in connection
with activities performed under this Agreement, including, without limitation, any improvements thereof. 



 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




 






    	page 2 of 13



    	 



    

  


		1.14	“Know-How” means all
information and materials, including, but not limited to, discoveries, improvements, processes, methods, protocols, formulas, data,
inventions, know-how and trade secrets, patentable or otherwise, which as of the Effective Date or during the Term: (i) are or
become Controlled by a Party or its Affiliates, (ii) are not generally known, and (iii) are necessary or useful to develop,
manufacture, market, use or sell the Compound.



 


		1.15	“Party” means Consultant,
TES or INTERCEPT, individually, and “Parties” means Consultant, TES and INTERCEPT, collectively.



 


		1.16	“Patent Rights” means
any and all patents and patent applications (which for the purpose of this Agreement shall be deemed to include certificates of
invention and applications for certificates of invention), including divisionals, continuations, continuations-in-part, reissues,
renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, and
the like, of any such patents and patent applications, and foreign equivalents of the foregoing, and any other patents and patent
applications claiming priority back to any of the foregoing. 



 


		1.17	“Research Program”
means the written research plan attached as Exhibit A to this Agreement, setting forth the research activities and services to
be conducted by TES and through the Services provided by the Consultant. 



 


		1.18	“Term” means the term
of this Agreement as defined in Section 7.1 of this Agreement.



 


		1.19	“Third Party” means
an entity other than Consultant, or TES and its Affiliates. 



  


Article
2: SCOPE AND MANAGEMENT OF THE RESEARCH PROJECT


 


		2.1	Research activities



 


Conduct
and INTERCEPT Payments to Consultant


 


Consultant shall provide to
INTERCEPT and TES scientific guidance, supervision and coordination of research activities (such activities to include but not
be limited to synthetic, computational and analytical chemistry and screening) to discover, identify, optimize and develop Compounds
as set forth in the Research Program.


 


Consultant agrees
to make himself available to render the Services as requested by Intercept at such times and locations as may be mutually agreed
and to perform such Services in a professional and workmanlike manner. INTERCEPT will pay to Consultant fifty thousand euros
(€50,000) and one hundred thousand euros (€100,000) on an annualized basis for consulting services and Inventions, Know
How, Improvements and Patent Rights, respectively, during the Term of this Agreement payable as follows: €37,500 on October
31, 2011; €37,500 on January 31, 2012; €37,500 on April 30, 2012 and €37,500 on July 31, 2012. All such payments
shall be made in Euros, the lawful currency of the European Community, within ten (10) business days of such payment due date.
Consultant will also be eligible for a fifty thousand euro performance (€50,000) bonus based on the success of the Research
Collaboration.


 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




 






    	page 3 of 13



    	 



    




 


		2.2	Taxes and Withholding



 


All
payments due and payable under this Agreement will be made without any deduction or withholding for or on account of any tax unless
such deduction or withholding is required by applicable laws. If INTERCEPT is so required to deduct or withhold, INTERCEPT will
(a) promptly notify the Consultant of such requirement, (b) pay to the relevant authorities the full amount required to be deducted
or withheld promptly upon the earlier of determining that such deduction or withholding is required or receiving notice that such
amount has been assessed against the other Party, and (c) promptly forward to Consultant an official receipt (or certified copy)
or other documentation reasonably acceptable to Consultant evidencing such payment to such authorities.


 


Article
3: INTELLECTUAL PROPERTY


 


		3.1	Inventorship, Ownership And Disclosure of Intellectual
Property



 


Inventorship and ownership


 


Inventorship
of inventions shall be determined in accordance with rules and guidelines regarding inventorship as established under the applicable
patent law of the country in which the patent issued or the application is pending. Consultant agrees that all Inventions made
from January 1, 2011 through the Term shall be owned by INTERCEPT and all original works of authorship that are made by Consultant
(solely or jointly with others) within the Services and scope of the Research Project and which are protectable by copyright are
“works made for hire” pursuant to the United States Copyright Act (17 U.S.C. Section 101). Consultant hereby assigns
to INTERCEPT all of his rights, titles and interests from January 1, 2011 through the Term in and to all such Inventions, Know-How,
Patent Rights, and original works of authorship and any and all related patents, copyrights, trademarks,
trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere
and hereby appoints any officer of INTERCEPT as its duly authorized representative to execute, file, prosecute and protect the
same before any government agency, court or authority. Upon the request of INTERCEPT, Consultant shall execute such further assignments,
documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to INTERCEPT and
to assist INTERCEPT in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in
any foreign country with respect to any Invention and original works of authorship. Consultant also hereby waives all claims to
moral rights in any Inventions.  








 


Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.


 








    	page 4 of 13



    	 



    

 


Disclosure 


 


In the event
that from January 1, 2011 and during the Term, Consultant has developed or develops any Inventions with respect to a Compound,
Consultant shall furnish INTERCEPT with timely written notice of such Inventions. As to such Inventions that are Improvements,
Consultant shall furnish INTERCEPT with a complete written disclosure of any such Improvements promptly after realization of such
Improvements, with the goal of making such disclosure within a twenty (20) day period. When Data have been generated relating to
Inventions or Improvements, Consultant shall furnish INTERCEPT with a data package which, in the Consultant’s reasonable
opinion, contains all material information, Know-How and other Data available that would be useful to implement such Inventions
or Improvements. Should a decision be made to file a patent application with respect to an Invention or Improvement, Consultant
shall help with the drafting of the patent application and shall provide any additional supplemental Data as appropriate after
filing of the patent application.


 


Article
4: CONFIDENTIALITY


 


		4.1	Confidentiality; Exceptions



 


Except as otherwise provided
in this Agreement, Consultant agrees that, during the Term and for as long as INTERCEPT is under an obligation to keep the information
confidential due to its own contractual requirements with Third Parties, but in any case no less than five (5) years thereafter,
all non-public, proprietary invention disclosures, Know-How, data, and technical, financial, promotional, commercial and other
information of any nature whatsoever (collectively, “Confidential Information”), disclosed or submitted, either
orally or in writing (including, without limitation by electronic means) or through observation, by INTERCEPT to Consultant (the
“Receiving Party”) hereunder shall be received and maintained by the Receiving Party in strict confidence, shall
not be used for any purpose or disclosed to any Third Party other than the purposes expressly permitted by this Agreement, (including,
without limitation in connection with any publications, presentations or other disclosures). Notwithstanding the foregoing, the
Receiving Party may, subject to the provisions of this Agreement, disclose the Confidential Information to those of its Affiliates’
directors, officers, employees, agents and consultants, contractors that have a need to know such Confidential Information to achieve
the purposes of this Agreement; provided, however, that such Party shall ensure that its Affiliates’ or sublicensees’
directors, officers, employees, agents, consultants, or contractors to whom disclosure is to be made are bound by, and take reasonable
efforts to ensure compliance with, the confidentiality and use provisions at least as restrictive as those contained in this Article
4 hereof. Consultant will promptly notify INTERCEPT upon discovery of any unauthorized use or disclosure of the Confidential Information.
Confidential Information belongs to and shall remain the property of INTERCEPT.


 


		4.2	Authorized Disclosure



 


A Receiving Party may disclose
Confidential Information hereunder solely to the extent such disclosure is reasonably necessary in connection with submissions
to or any requirements of any Regulatory Authority for the purposes of this Agreement or, complying with applicable laws or the
rules of any relevant stock exchange or securities commission; provided that in the event of any such disclosure of the Confidential
Information by the Receiving Party, the Receiving Party will, except where impracticable, give reasonable advance notice to INTERCEPT
of such disclosure requirement (so that the INTERCEPT may seek a protective order and or other appropriate remedy or waive compliance
with the confidentiality provisions of this Article 4) and will use Commercially Reasonable Efforts to secure confidential treatment
of such Confidential Information required to be disclosed.





 


Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.


 








    	page 5 of 13



    	 



    

  


		4.3	Return of Confidential Information



 


The Receiving Party shall keep
Confidential Information belonging to INTERCEPT in appropriately secured locations. Upon the expiration or termination of this
Agreement, any and all Confidential Information possessed in tangible form by a Receiving Party or its Affiliates, or its or any
of their officers, directors, employees, agents, consultants, or contractors , shall, upon written request, be immediately returned
to INTERCEPT (or destroyed if so requested) and not retained by the Receiving Party, its Affiliates, or any of their officers,
directors, employees, agents, consultants, or contractors; provided, however, that the Receiving Party may retain one (1) copy
of any Confidential Information in an appropriately secured location, in order to demonstrate compliance with the terms of this
Agreement or which by applicable laws it must retain, for so long as such applicable laws require such retention but thereafter
shall dispose of such retained Confidential Information in accordance with applicable laws or this Article 4.3.


 


		4.4	Publications
and Announcements



 


Consultant agrees not to publish
any Confidential Information without INTERCEPT’s consent, and agrees not to publish any information related to an Invention
not already protected by a Patent Rights without the consent of INTERCEPT.


 


ARTICLE
5: REPRESENTATIONS, WARRANTIES AND COVENANTS


 


		5.1	Representations and Warranties of Intercept Concerning
Corporate Authorization



 


INTERCEPT represents and warrants
to Consultant that it is duly organized and validly existing and in good standing under the laws of the jurisdiction of its organization
and is duly authorized to enter into, execute and deliver this Agreement, and to carry out and otherwise perform its obligations
hereunder.


 


		5.2	Representations, Warranties and Covenants of Consultant



 


Consultant represents and warrants
to INTERCEPT that Consultant is duly authorized to enter into, execute and deliver this Agreement, and to carry out and otherwise
perform his obligations hereunder.


 


There
are not as of the Effective Date, nor have there been over the six (6) month period immediately preceding the Effective Date, any
claims, lawsuits, arbitrations, legal or administrative or regulatory proceedings, charges, complaints or investigations by any
Regulatory Authority (except in the ordinary course of the granting of patents and proceedings relating thereto) or other third
party against Consultant;





 


Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.


 








    	page 6 of 13



    	 



    

 


Consultant
hereby represents and warrants to INTERCEPT that (a) Consultant’s execution of this Agreement (including the performance
of the Services under this Agreement) does not and shall not during the Term conflict with any obligations of Consultant to the
University, whether under any applicable laws or otherwise, and (b) Consultant is currently under no contractual or other restriction
or obligation which is inconsistent with Consultant’s execution of this Agreement (including the performance of the Services
or any other obligation hereunder).


 


		5.3	Negative covenants



 


Consultant
covenants that, during the Term, (a) Consultant shall not enter into any agreement, whether written, oral or otherwise, that conflicts
with or otherwise restricts or impedes his ability to fully perform the Services or any other obligations of his under this Agreement
and (b) Consultant shall not take any action or fail to take any action with respect to any existing agreement (whether written,
oral or otherwise) or any agreement (whether written, oral or otherwise) entered into during the Term that would create a conflict
or otherwise impede his ability to fully perform the Services or any other obligations of his under this Agreement. Other than
this Agreement, Consultant hereby represents that he is not party to any existing written or oral agreement, arrangement, understanding
or other relationship pursuant to which he is obligated to render advice and services to a commercial entity in the synthetic,
computational and analytical chemistry and screening to discover, identify, optimize and/or develop any chemical entity and/or
active ingredient which is a selective or non-selective TGR5 receptor agonist. Consultant hereby agrees and acknowledges that,
during the Term of this Agreement (as defined below), he will not enter into any written or oral agreement, arrangement, understanding
or other relationship pursuant to which he is obligated to render advice and services in the synthetic, computational and analytical
chemistry and screening to discover, identify, optimize and/or develop any chemical entity and/or active ingredient which is selective
or non-selective TGR5 agonists.


 


ARTICLE
6: INDEMNIFICATION


 


		6.1	Indemnification
by Consultant



 


Consultant hereby agrees to save,
defend, and hold INTERCEPT, its Affiliates and their officers, directors, employees and agents harmless from and against any and
all direct and foreseeable losses, damages, liabilities, costs and expenses resulting from any claims, demands, actions and other
proceedings by any of its Affiliates, employee or consultant or Third Party (collectively, “Losses”) to the
extent resulting directly from or arising directly out of: (a) any material breach by Consultant of any representation, warranty,
covenant under this Agreement or (b) the gross negligence or willful misconduct of Consultant, or (c) the unauthorized use by Consultant
of INTERCEPT Data and Regulatory Documents.





 


Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.


 








    	page 7 of 13



    	 



    

  


ARTICLE
7: TERM, TERMINATION, survival


 


		7.1	Term



 


This
Agreement shall commence on the Effective Date and shall expire twelve months from the Effective Date, unless extended by INTERCEPT
in its sole discretion by way of an amendment to the Agreement
of one additional year (the “Term”). 


 


		7.2	Termination 



 


Termination
for Breach. If either Consultant, on the one hand, or INTERCEPT, on the other hand, materially breaches any provision of this
Agreement and fails to remedy such breach within thirty (30) days after receipt of notice in writing of such breach from the other
party, such other party, at its option, and in addition to any other remedies that may be available to such other party, may terminate
this Agreement by sending written notice of termination to the breaching party.


 


		7.3	Survival



 


Termination, relinquishment
or expiration of this Agreement for any reason shall be without prejudice to any right or obligation which shall have accrued prior
to such termination, relinquishment or expiration, including but not limited to accrued financial rights and obligations. The following
Articles of this Agreement shall survive expiration or termination of this Agreement for any reason: 2.2, 3, 4, 5, 7, 8 and 9.


 


ARTICLE
8: GOVERNING LAW AND DISPUTE RESOLUTION


 


		8.1	Governing law



 


This Agreement shall be governed
by and construed under the laws of New York, NY US without giving effect to the conflict of law principles thereof.


 


		8.2	Dispute resolution



 


Any
dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall
be resolved as follows:


 


The designated executive
of INTERCEPT and Consultant shall meet to attempt to resolve such disputes. If such persons cannot resolve such disputes within
thirty (30) days after any party requests such a meeting, then any party may make a written demand for formal dispute resolution.


 


Any dispute, controversy
or claim not resolved shall be finally settled by binding arbitration conducted in the English language in New York, New York,
USA by one arbitrator under the commercial arbitration rules of the American Arbitration Association (“AAA”),
which shall administer the arbitration and act as appointing authority. The arbitrator shall be authorized to grant interim relief,
including to prevent the destruction of goods or documents involved in the dispute, protect trade secrets and provide for security
for a prospective monetary award. The award of the arbitrator shall be the sole and exclusive remedy of the parties and shall be
enforceable in any court of competent jurisdiction, subject only to revocation on grounds of fraud or clear bias on the part of
the arbitrators.





 


Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




 






    	page 8 of 13



    	 



    




 


Notwithstanding
anything contained in this Section 8.2 to the contrary, each party shall have the right to institute judicial proceedings against
the other party or anyone acting by, through or under such other party, in order to enforce the instituting party’s rights
hereunder through reformation of contract, specific performance, injunction or similar equitable relief.


 


ARTICLE
9: ASSIGNMENT, SUBCONTRATING, NO THIRD PARTY RIGHTS, BINDING AGREEMENT


 


		9.1	Assignment



 


Consultant
may not assign or otherwise transfer its rights or obligations under this Agreement without the prior written consent of INTERCEPT.


 


		9.2	No
                                                                                    Third Party Rights



 


The representations, warranties,
covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted
assigns and a person who is not a Party to this Agreement may not enforce any of its terms unless otherwise provided.


 


		9.3	Binding
                                                                                    Agreement



 


This Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this
Agreement shall be null and void.


 


		9.4	Force majeure



 


Neither Party shall be liable
to the other Party for damages or losses on account of failure of performance by the defaulting Party to the extent the failure
is occasioned by regulatory action, war, fire, explosion, flood, strike, lockout, embargo, act of God, or any other similar cause
beyond the reasonable control of the defaulting Party. The Party claiming force majeure shall as soon as reasonably practicable
notify the other Party in writing setting forth the nature of such force majeure event, and shall use reasonable efforts to resume
performance of its obligations hereunder as soon as reasonably practicable after such force majeure event ceases. If any force
majeure event continues for more than one hundred eighty (180) days, and such event prevents a Party from performing a material
obligation under this Agreement, then the other Party may terminate this Agreement upon written notice to the affected Party.


 


		9.5	Further Actions



 


Each Party agrees to execute,
acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.


 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




  



    	page 9 of 13



    	 



    

 





		9.6	Regulatory
Approvals; Compliance with Law


  


The Parties shall make all
filings with Regulatory Authorities as shall be required by applicable laws in connection with this Agreement and the activities
contemplated hereunder or thereunder. In fulfilling its obligations under this Agreement each Party agrees to comply in all material
respects with all applicable laws.


 


		9.7	Public Announcement



 


Except for such disclosure
as is deemed necessary, in the reasonable judgment of a Party to comply with applicable laws, no announcement, news release, public
statement, publication or presentation relating to the existence of this Agreement, or the terms hereof or thereof, will be made
without the other Party’s prior written approval, which approval shall not be unreasonably withheld. Notwithstanding the
foregoing, each Party consents to references to it in reports or documents or other disclosures sent to stockholders or filed with
or submitted to any Regulatory Authority or stock exchange or as may be required by law to be made. However, the Party making such
references shall afford the other Party the prior opportunity to review the text of any such report, document or other disclosure,
and shall use its best efforts to comply with any reasonable requests regarding changes to such reports, documents and other disclosures
which are provided to it by the other Party in a timely manner. The Parties each agree that once approval for disclosure of information
subject to this Article has been obtained, the Party that requested such approval shall be entitled to use such information substantially
in the form initially presented without an obligation to seek further approval.


 


		9.8	Notices



 


All notices required or permitted
to be given under this Agreement, shall be in writing and shall be deemed given if delivered personally or by facsimile transmission
receipt verified, mailed by registered or certified mail return receipt requested, postage prepaid, or sent by express courier
service, to the Parties at the following addresses, or at such other address for a Party as shall be specified by like notice,
provided that notices of a change of address shall be effective only upon receipt thereof.


 


If to INTERCEPT, addressed
to:


 


INTERCEPT PHARMACEUTICALS, INC.


18 Desbrosses Street


New York, NY 10013


Attention:
Dr. Mark Pruzanski, Chief Executive Officer


 


If to Consultant
addressed to:


 


Professor Roberto
Pellicciari


Via U. Rocchi,
60


Perugia, Italy
06123


 


The date of receipt of any
notice given under this Agreement shall be deemed to be (i) the date given if delivered personally or by facsimile transmission
receipt verified, (ii) seven (7) days after the date mailed if mailed by registered or certified mail return receipt requested,
postage prepaid, and (iii) two (2) days after the date sent if sent by express courier service.


 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




  



    	page 10 of 13



    	 



    

 


		9.9	Waiver



 


No failure of either Party
to exercise and no delay in exercising any right, power or remedy in connection with this Agreement (each a “Right”)
will operate as a waiver thereof, nor will any single or partial exercise of any Right preclude any other or further exercise of
such Right or the exercise of any other Right.


 


		9.10	Disclaimer
of Agency



 


The relationship between INTERCEPT
and Consultant established by this Agreement is that of independent contractors, and nothing contained herein shall be construed
to (i) give either Party the power to direct or control the day-to-day activities of the other, (ii) constitute the Parties as
the legal representative or agent of the other Party or as partners, joint venturers, co-owners or otherwise as participants in
a joint or common undertaking, or (iii) allow either Party to create or assume any liability or obligation of any kind, express
or implied, against or in the name of or on behalf of the other Party for any purpose whatsoever, except as expressly set forth
in this Agreement.


 


		9.11	Ambiguities



 


Ambiguities, if any, in this
Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.


 


		9.12	Headings and
Article References



 


The Article headings and references
contained herein are for the purposes of convenience only and are not intended to define or limit the contents of said Articles,
except that any conflict between an Article reference number and any textual reference to the Article title noted next to such
reference, will resolved in favor of the textual reference.


 


		9.13	Severability



 


If any term, covenant or condition
of this Agreement or the application thereof to any Party or circumstance shall, to any extent, be held to be invalid or unenforceable
by a court or administrative agency of competent jurisdiction, then (i) the remainder of such documents, or the application of
such term, covenant or condition to Parties or circumstances other than those as to which it is held invalid or unenforceable,
shall not be affected thereby and each term, covenant or condition of such documents shall be valid and be enforced to the fullest
extent permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof
in good faith in order to provide a reasonably acceptable alternative to the term, covenant or condition of such documents or the
application thereof that is invalid or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement
are to be effectuated.


 


		9.14	Counterparts



 


This Agreement may be executed
in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.


 


In witness whereof, the Parties
have executed this Agreement by their proper officers as of the date and year first above written.


 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




 






    	page 11 of 13



    	 



    




 


INTERCEPT PHARMACEUTICALS, INC. 


 


/s/ Mark Pruzanski





Name: Mark Pruzanski


 


Title: President and Chief Executive Officer


 


CONSULTANT 


 


/s/ Roberto Pellicciari


Name: Roberto Pellicciari


 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




 






    	page 12 of 13



    	 



    

  


EXHIBIT A


 


Servier- Intercept Research Plan


 


[***]


 





Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.




 






    	page 13 of 13